| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2023
Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN, May 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced...
-
May 20, 2023
Late-breaking data at Heart Rhythm 2023 underscore performance of first-of-its-kind investigational defibrillator with the lead placed under the breastbone, outside the heart and veins...
-
May 16, 2023
AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM DUBLIN, May 16, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today...
-
May 1, 2023
New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership DUBLIN, May 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...
-
Apr 21, 2023
Available in Europe since 2020, this new system delivers the strongest clinical outcomes and best user experience to-date within the Medtronic family of pumps DUBLIN, April 21, 2023 /PRNewswire/...
-
Apr 1, 2023
New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation DUBLIN and DENVER, April 1, 2023 /PRNewswire/ -- Medtronic plc...
-
Mar 15, 2023
First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023
-
Mar 13, 2023
Recognition honors companies demonstrating business integrity through best-in-class ethics, compliance, and governance practices DUBLIN, March 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a...
-
Mar 2, 2023
The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase...
-
Feb 24, 2023
A second randomized controlled trial sponsored by JDRF also demonstrates superiority of automated insulin pump as first-in-line therapy for children with type 1 diabetes DUBLIN and BERLIN, Feb....
